Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome

Documenti analoghi

• Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
  di: Philips, Ashwin, et al.
  Pubblicazione: (2018)
• Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
  di: Cammalleri, Lisa, et al.
  Pubblicazione: (2007)
• A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
  di: Vadhan-Raj, S., et al.
  Pubblicazione: (2012)
• One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies
  di: Azim, Hamdy A, et al.
  Pubblicazione: (2013)
• Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series
  di: Latha, S. M., et al.
  Pubblicazione: (2015)